Insight Molecular Diagnostics Inc. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Insight Molecular Diagnostics Inc. (IMDX) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$60.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2025-03-24
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-12-31 was -$33.51M.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-09-30 was -$13.49M.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-06-30 was -$4.59M.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-03-31 was -$9.34K, a 290.55% decline year-over-year.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was -$60.93M.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was -$25.80M.
- Insight Molecular Diagnostics Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$19.13M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month as first filed | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | -$33.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$47.00M derived: sum of 2 quarters · filed 2025-03-24 | -$51.59M derived: sum of 3 quarters · filed 2025-03-24 | -$60.93M 10-K · filed 2025-03-24 | |
| 2024-09-30 | -$13.49M 10-Q · filed 2024-11-12 | -$18.08M derived: sum of 2 quarters · filed 2024-11-12 | -$27.41M 10-Q · filed 2024-11-12 | -$34.28M derived: sum of 4 quarters · filed 2025-03-24 | |
| 2024-06-30 | -$4.59M 10-Q · filed 2024-08-08 | -$13.92M 10-Q · filed 2024-08-08 | -$20.79M derived: sum of 3 quarters · filed 2025-03-24 | -$27.48M derived: sum of 4 quarters · filed 2025-03-24 | |
| 2024-03-31 | -$9.34K 10-Q · filed 2024-05-15 | -$16.20M derived: sum of 2 quarters · filed 2025-03-24 | -$22.89M derived: sum of 3 quarters · filed 2025-03-24 | -$31.54M derived: sum of 4 quarters · filed 2025-03-24 | |
| 2023-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$22.88M derived: sum of 2 quarters · filed 2025-03-24 | -$31.53M derived: sum of 3 quarters · filed 2025-03-24 | -$25.80M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$6.69M 10-Q · filed 2024-11-12 | -$15.33M derived: sum of 2 quarters · filed 2024-11-12 | -$9.60M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$8.64M 10-Q · filed 2024-08-08 | -$2.92M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $4.90K 10-Q · filed 2024-05-15 | $4.90M 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | -$19.13M 10-K · filed 2024-04-16 | ||||
| 2022-03-31 | -$3.41M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |